Palatin exclusively licensed North American rights to develop and commercialize bremelanotide to AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG). The anticipated filing date in the U.S. for a new drug application for bremelanotide, an on-demand treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, is early 2018, with an anticipated approval and launch by early 2019.